clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kruppa A et al. Immediate reaction to roxithromycin and prick test cross-sensitization to erythromycin and clarithromycin. 1998 Dermatology (Basel) pmid:9621142
Ishii K et al. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. 1998 Drug Dev Ind Pharm pmid:15605442
van Westrhenen R et al. Pneumonia and glomerulonephritis caused by Mycoplasma pneumoniae. 1998 Nephrol. Dial. Transplant. pmid:9870493
Waddell ST et al. Synthesis and antibacterial activity of O-methyl derivatives of azalide antibiotics: II. 6-OME derivatives via clarithromycin. 1998 Bioorg. Med. Chem. Lett. pmid:9871759
Lee CL et al. One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers. 1998 J. Formos. Med. Assoc. pmid:9872028
Suzuki J et al. Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer. 1998 J. Clin. Gastroenterol. pmid:9872515
Sakaki N et al. Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. 1998 J. Clin. Gastroenterol. pmid:9872520
Yoshida Y et al. Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. 1998 Bioorg. Med. Chem. Lett. pmid:9873455
Sakurai N et al. Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. 1998 Bioorg. Med. Chem. Lett. pmid:9873510
Komori T et al. Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. 1998 Res. Commun. Mol. Pathol. Pharmacol. pmid:9874281
Kondoh K and Hashiba M [Inhibitory effect of macrolide antibiotics on biofilm formation by Pseudomonas aeruginosa]. 1998 Nippon Jibiinkoka Gakkai Kaiho pmid:9493436
Mukunda BN et al. Clarithromycin therapy for bacillary peliosis did not prevent bacillary angiomatosis. 1998 Clin. Infect. Dis. pmid:9770180
Stack WA et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. 1998 Am. J. Gastroenterol. pmid:9772054
Adamek RJ and Bethke TD Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. 1998 Am. J. Gastroenterol. pmid:9772056
Stolte M et al. Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male. 1998 Z Gastroenterol pmid:9773482
Pina M et al. Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. 1998 J. Clin. Microbiol. pmid:9774580
Hawkey CJ et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. 1998 Lancet pmid:9759744
Nelson KG et al. Results of operation in Mycobacterium avium-intracellulare lung disease. 1998 Ann. Thorac. Surg. pmid:9725364
Sung JJ et al. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. 1998 Aliment. Pharmacol. Ther. pmid:9726384
Mégraud F and Doermann HP Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. 1998 Gut pmid:9764043
Pazzi P et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. 1998 Aliment. Pharmacol. Ther. pmid:9726385
Heald AE et al. Taste and smell complaints in HIV-infected patients. 1998 AIDS pmid:9764787
Harris AW et al. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. 1998 Aliment. Pharmacol. Ther. pmid:9726387
Perri F et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. 1998 Ital J Gastroenterol Hepatol pmid:9675647
Talley NJ et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9678811
Hoppe JE and Bryskier A In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). 1998 Antimicrob. Agents Chemother. pmid:9559823
Ricciardiello L et al. Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. 1998 Aliment. Pharmacol. Ther. pmid:9678812
Cammarota G et al. One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. 1998 Aliment. Pharmacol. Ther. pmid:9678813
Louw JA et al. Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. 1998 Aliment. Pharmacol. Ther. pmid:9678814
Kashuba AD and Amsden GW Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1998 Antimicrob. Agents Chemother. pmid:9527816
Bocheńska-Marciniak M et al. [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. 1998 Pol. Arch. Med. Wewn. pmid:10335027
Casswall TH et al. One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection. 1998 J. Pediatr. Gastroenterol. Nutr. pmid:9779970
Aberg JA et al. Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. 1998 J. Infect. Dis. pmid:9780266
González Carro P et al. [Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori]. 1998 Rev Esp Enferm Dig pmid:9780793
Gangadharam PR Clarithromycin for non-mycobacterial diseases? 1998 Int. J. Tuberc. Lung Dis. pmid:9783536
Hahn DL et al. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma. 1998 Ann. Allergy Asthma Immunol. pmid:9475566
Sakamoto M et al. [Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer]. 1998 Gan To Kagaku Ryoho pmid:9881083
Komori T et al. Effects of repeated clarithromycin administration on the pharmacokinetic properties of pindolol in rats. 1998 Biol. Pharm. Bull. pmid:9881659
Shafran SD et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. 1998 J. Infect. Dis. pmid:9419201
van Aarem A et al. Recurrent therapy resistant mastoiditis by Mycobacterium cheilonae abscessus, a nontuberculous mycobacterium. 1998 Int. J. Pediatr. Otorhinolaryngol. pmid:9596371
Koster F Paradoxical local response to therapy for Mycobacterium avium complex infection in four patients with AIDS. 1998 Clin. Infect. Dis. pmid:9597260
Comet R et al. [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. 1998 Gastroenterol Hepatol pmid:9549183
Carnicer J [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. 1998 Gastroenterol Hepatol pmid:9549199
Iwata M et al. [Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. 1998 Nippon Naika Gakkai Zasshi pmid:9549331
Rosina P et al. Fixed drug eruption from clarithromycin. 1998 Contact Derm. pmid:9506224
Carlson LD et al. Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. 1998 J. Clin. Microbiol. pmid:9508306
Sato K et al. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. 1998 J. Antimicrob. Chemother. pmid:9511040
Alegre Herrera S et al. [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. 1998 An Med Interna pmid:9522506
Kaeser YA et al. Severe hypotension and bradycardia associated with verapamil and clarithromycin. 1998 Am J Health Syst Pharm pmid:9825040
Hua J et al. Characterization of clinical isolates of Helicobacter pylori in Singapore. 1998 Microbios pmid:9785486
Clark CL et al. Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies. 1998 J. Clin. Microbiol. pmid:9817876
Björkholm B et al. Rapid PCR detection of Helicobacter pylori-associated virulence and resistance genes directly from gastric biopsy material. 1998 J. Clin. Microbiol. pmid:9817898
Arimori K et al. Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin. 1998 Biopharm Drug Dispos pmid:9818709
Sanfélix Genovés J et al. [Helicobacter pylori: 6-day triple therapy in duodenal ulcer]. 1998 Aten Primaria pmid:9670578
Cirioni O et al. In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii. 1998 J. Antimicrob. Chemother. pmid:9818742
de Boer WA et al. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. 1998 Am. J. Gastroenterol. pmid:9672338
Vrioni G et al. Treatment of disseminated Mycobacterium genavense infection in a murine model with ciprofloxacin, amikacin, ethambutol, clarithromycin and rifabutin. 1998 J. Antimicrob. Chemother. pmid:9818747
Martin SJ and Pendland SL Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila. 1998 J. Antimicrob. Chemother. pmid:9687103
Hafner R et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. 1998 Antimicrob. Agents Chemother. pmid:9517944
Fattorini L et al. Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. 1998 Antimicrob. Agents Chemother. pmid:9517960
Trivedi S et al. Clarithromycin and digoxin toxicity. 1998 Ann. Intern. Med. pmid:9518419
Laine L and Fendrick AM Helicobacter pylori and peptic ulcer disease. Bridging the gap between knowledge and treatment. 1998 Postgrad Med pmid:9519040
Petersen AM et al. [Resistance of Helicobacter pylori to clarithomycin]. 1998 Ugeskr. Laeg. pmid:9627511
Domingo D et al. High frequency of mutations at position 2144 of the 23S rRNA gene in clarithromycin-resistant Helicobacter pylori strains isolated in Spain. 1998 J. Antimicrob. Chemother. pmid:9630414
Fireman Z et al. Helicobacter pylori and peptic ulcer disease therapies: a survey of gastroenterologists in Israel. 1998 Helicobacter pmid:9631306
Battaglia G et al. Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. 1998 Helicobacter pmid:9631310
Miwa H et al. Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. 1998 Helicobacter pmid:9631313
Calvet Calvo X [Treatment of Helicobacter pylori infections]. 1998 Gastroenterol Hepatol pmid:9633184
Wang G et al. Genotypic characterization of clarithromycin-resistant and -susceptible Helicobacter pylori strains from the same patient demonstrates existence of two unrelated isolates. 1998 J. Clin. Microbiol. pmid:9705423
van der Wouden EJ et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. 1998 Am. J. Gastroenterol. pmid:9707042
Burman WJ et al. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 AIDS pmid:9708410
Holmberg SD et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. 1998 JAMA pmid:9459473
Dehesa M et al. [Comparison of 2 schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer]. 1998 Apr-Jun Rev Gastroenterol Mex pmid:10068730
Fennerty MB et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. 1998 Aug 10-24 Arch. Intern. Med. pmid:9701099
Mikamo H et al. Effects of long-term/low-dose clarithromycin on neutrophil count and interleukin-8 level in pyometra. 1998 Jan-Feb Chemotherapy pmid:9444409
Ziering W and McElvaine P Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. 1998 Jan-Feb Infection pmid:9505188
Langan C et al. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. 1998 Jul-Aug Int. J. Clin. Pract. pmid:9796558
Habu Y et al. Triple therapy with omeprazole, amoxicillin and clarithromycin is effective against Helicobacter pylori infection in gastric ulcer patients as well as in duodenal ulcer patients. Results of a randomized controlled trial in Japan. 1998 Jul-Aug Digestion pmid:9693202
Shafran SD Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. 1998 Jul-Sep Int. J. Infect. Dis. pmid:9831675
Venuta A et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. 1998 Jun-Jul J. Int. Med. Res. pmid:9718470
Fernández Bermejo M and García Grávalos R [Ebrotidine in the eradicating treatment of H. pylori]. 1998 Jun-Jul Gastroenterol Hepatol pmid:9711019
Oberg KC Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. 1998 Mar-Apr Pharmacotherapy pmid:9545160
Vakil N Treatment of H. pylori infection: the reality. 1998 Mar-Apr Yale J Biol Med pmid:10378357
Miehlke S et al. Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection. 1998 Nov-Dec Digestion pmid:9813387
Adelglass J et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. 1998 Nov-Dec Pharmacotherapy pmid:9855324
Tohnai A et al. Clarithromycin suppresses proliferation of rat nasal epithelium exposed to endotoxin. 1998 Nov-Dec Am J Rhinol pmid:9883303
Mermelstein HT Clarithromycin-induced delirium in a general hospital. 1998 Nov-Dec Psychosomatics pmid:9819955
Anzueto A et al. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. 1998 Sep-Oct Clin Ther pmid:9829441
Kihira K et al. [Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections]. 1999 Nippon Rinsho pmid:10036953
Goto T et al. [Erosive duodenitis after eradication therapy for Helicobacter pylori]. 1999 Nihon Shokakibyo Gakkai Zasshi pmid:10047687
Dionisio D et al. Encephalitis caused directly by Mycoplasma pneumoniae. 1999 Scand. J. Infect. Dis. pmid:10576133
Yatsunami J et al. Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. 1999 Cancer Lett. pmid:10660084
Catalano F et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. 1999 Helicobacter pmid:10469192
Yoshida Y et al. Synthesis and anti-Helicobacter pylori activity of FR182024, a new cephem derivative. 1999 Bioorg. Med. Chem. Lett. pmid:10560737
Kamada T et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. 1999 Helicobacter pmid:10469195
Hewitt RG et al. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. 1999 AIDS pmid:10449290
Hoffman JS et al. Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. 1999 Aliment. Pharmacol. Ther. pmid:10215735
Burgess DS et al. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. 1999 Ann Pharmacother pmid:10630825
Xiao SD et al. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. 1999 Aliment. Pharmacol. Ther. pmid:10102963
Yajima T et al. Optimum spray congealing conditions for masking the bitter taste of clarithromycin in wax matrix. 1999 Chem. Pharm. Bull. pmid:10071855